Diphereline S.R. is commonly used to help with symptoms related to systemic imbalance in several therapeutic areas. The primary therapeutic benefit across all uses contributes to easing the overall symptom load in conditions where symptoms may intensify temporarily. This medication is commonly used to help with symptoms that create noticeable physiological strain. It is generally applied in addressing conditions marked by increased physiological stress, including prostate cancer, endometriosis, uterine fibroids, and Central Precocious Puberty (CPP).

Quick Fact: Relief for Symptoms of Systemic Imbalance

For adult patients, its use helps address symptoms that create noticeable physiological strain and may assist with managing painful symptom clusters associated with gynecological conditions. In pediatric patients, it is considered relevant for easing symptoms associated with CPP. The goal is to provide support that helps ease the overall symptom burden and supports general well-being during symptomatic phases.

Regulatory References

1. NIH MedlinePlus Drug Information overview

Who Can and Cannot Use Diphereline S.R. (Triptorelin)?

Official regulatory documents strictly define the patient populations eligible for Diphereline S.R., focusing on specific age groups and contraindications.

---

Populations Permitted for Use

Use is officially permitted for Adult Males (for advanced prostate cancer), Adult Females (for approved gynecological conditions), and Pediatric Patients (children aged two years and older) specifically for Central Precocious Puberty (CPP). Use in children for CPP is restricted based on bone maturation age, with treatment typically ceasing when bone age reaches puberty thresholds (e.g., beyond 12–14 years, depending on sex).

---

Absolute Contraindications

Diphereline S.R. must not be used in patients with a known hypersensitivity to the active ingredient Triptorelin, any other GnRH analogue, or any components of the product. The medicine is also strictly contraindicated in women who are pregnant or who are breastfeeding.

---

Conditional Use and Restrictions

Use is restricted and requires close monitoring for Adult Males with prostate cancer who are at high risk of spinal cord compression or ureteral obstruction. The medicine is generally permitted for patients with renal or hepatic impairment, as most regulatory labels state no specific dose adjustment is required in these groups.

Interactions with Other Medicines and Products

The official interaction profile for Diphereline S.R. (Triptorelin) focuses on pharmacodynamic and procedural considerations, as regulatory documents note that Triptorelin is unlikely to be involved in clinically significant interactions mediated by Cytochrome P450 (CYP) enzymes or drug transporters.

Pharmacodynamic Interactions

Caution is advised when co-administering Diphereline S.R. with medicines known to prolong the QT interval. Androgen Deprivation Therapy, which is achieved by Triptorelin, may cause a modest prolongation of the QT interval. This requires careful assessment when prescribing concomitant medications such as Class IA and Class III antiarrhythmics or certain antipsychotics.

Additionally, caution is recommended with drugs that raise prolactin levels, as these can potentially reduce the sensitivity of pituitary GnRH receptors.

Procedural and Substance Cautions

A procedural caution exists for patients receiving anti-coagulants (e.g., Warfarin). Due to the intramuscular route of administration, the co-administration of these medicines increases the risk of haematoma formation at the injection site.

Separately, patient information notes that the potential side effect of dizziness or light-headedness may be exacerbated by alcohol consumption.

How Diphereline S.R. Works: Mechanism of Action

Diphereline S.R. contains triptorelin, a synthetic analog of gonadotropin-releasing hormone (GnRH), that acts on the Hypothalamic-Pituitary-Gonadal (HPG) axis, the primary endocrine system regulating sex hormones. Triptorelin initially functions as a GnRH agonist, binding to receptors on the gonadotroph cells of the pituitary gland and causing temporary stimulation.

The sustained, continuous presence of the slow-release drug leads to the desensitization and downregulation of these GnRH receptors. This transformation of receptor activity results in a functional antagonist effect, causing a profound, continuous inhibition of the release of the gonadotropins, Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH).

This sustained suppression of LH and FSH removes the necessary trophic stimulus for the gonads (testes and ovaries). The resulting molecular cascade reduces the production of circulating sex steroids (testosterone and estradiol) to castrate levels. The physiological consequence is the induction of a state of chemical hypogonadism, characterized by reduced activity in sex steroid-dependent tissues.

How to Use Diphereline S.R.

Diphereline S.R., a prolonged-release depot formulation of triptorelin, is administered through intramuscular (IM) injection as the primary route, though deep subcutaneous (SC) injection may be used for the 3.75 mg regimen in certain contexts. Administration must be performed by a physician or qualified healthcare provider in a supervised setting, as the product is a powder requiring reconstitution prior to use. Intravascular injection is strictly prohibited due to the microparticle suspension nature of the drug.

---

Official Dosing and Frequency

Administration is based on the specific product strength to ensure sustained release over a fixed, non-negotiable interval. No dose adjustments are required for patients with renal or hepatic impairment.

Strength	Standard Adult Dosing Interval
3.75 mg	Once every 4 weeks (monthly)
11.25 mg	Once every 12 weeks (3 months)
22.5 mg	Once every 24 weeks (6 months)

---

Administration Protocol

The powder must be reconstituted with the provided sterile diluent (Sterile Water for Injection) immediately before use. The resulting suspension must be administered without delay (typically within 1–2 minutes) to prevent sedimentation of the microgranules. The injection site, usually in the buttock or thigh, should be alternated periodically with each administration.

If a scheduled dose is missed, it should be administered as soon as possible, and the subsequent dosing schedule should follow the fixed interval from that date forward. Treatment duration is often long-term for prostate cancer but is time-limited (e.g., maximum 6 months) for gynecological conditions like endometriosis. Pediatric dosing for Central Precocious Puberty (CPP) may be weight-based or a fixed 22.5 mg every 24 weeks.

Research Evidence / Overview of Studies for Diphereline S.R.

---

Evidence for Use in Prostate Cancer

This section will summarize the types of high-level studies, such as Randomized Controlled Trials (RCTs) and meta-analyses, that have explored whether Triptorelin depot administration was associated with changes in hormonal markers (like testosterone) and survival patterns in adult men with hormone-dependent prostate cancer.

Research has extensively examined the use of Diphereline S.R. in adult men with prostate cancer. The evidence base includes a range of studies, such as RCTs which compared Triptorelin to other hormonal treatments, as well as Phase III open-label studies. The main goals of this research included monitoring how Triptorelin administration related to serum testosterone levels and how it impacts overall survival and biomarkers like Prostate-Specific Antigen (PSA). Studies reported measurements of testosterone levels that were often observed to be in the range of hormonal suppression targets (castrate range), which is the hormonal focus examined in the studies. While data show patterns related to changes in the PSA biomarker, certainty remains low for some specialized questions, and evidence is limited regarding the direct comparison of Triptorelin to certain newer therapies in long-term overall survival analyses.

---

Evidence for Use in Central Precocious Puberty (CPP)

This part will describe the structural evidence, including Pivotal Phase III trials and long-term follow-up studies, that investigated the ability of Triptorelin depot to suppress hormonal activity and affect skeletal maturation in children with Central Precocious Puberty.

The evidence for using Diphereline S.R. in children with CPP is supported by Pivotal Phase III studies that focused on specific treatment protocols, primarily using single-arm studies in children diagnosed with gonadotropin-dependent Central Precocious Puberty. The primary focus of these studies was tracking the pattern of pre-pubertal Luteinizing Hormone (LH) levels. Researchers also explored auxological outcomes, which are related to growth, including changes in the rate of skeletal maturation (bone age) and Predicted Adult Height (PAH). Research described patterns related to symptom evolution in the observed populations, specifically documenting the stabilization or regression of secondary sexual characteristics over the defined time intervals. However, comparative evidence is lacking against untreated groups in those same trials, and long-term effects are not fully established regarding final height results across all treated populations.

---

Research Gaps and Areas of Uncertainty

This final section will synthesize the main limitations of the existing evidence, clarifying where the data may be restricted by short follow-up periods, small sample sizes, or inconsistencies across trials, indicating where further research is necessary.

While research contributes to the broader evidence landscape, several areas of uncertainty remain. Long-term effects are not fully established regarding the durability of the effect in certain conditions, especially those with short-term treatment protocols like uterine fibroids. For some functional outcomes, such as quality of life or specific pain metrics in gynecological conditions, evidence quality varies across studies, sometimes due to modest sample sizes or heterogeneity (differences) in the study designs. Furthermore, comparative evidence is lacking in certain areas; for example, some pivotal trials for the depot formulation were non-comparative (single-arm) rather than head-to-head trials against a placebo or other active control.

Common questions about Diphereline S.R. (FAQ)

---

Q: Can Diphereline S.R. be injected by the patient at home?

A: Diphereline S.R. is supplied as a powder that requires reconstitution into a suspension immediately prior to use. Official documentation specifies that the injection is intended to be administered by a physician or qualified healthcare provider in a supervised clinical setting, and not by the patient at home.

---

Q: What is the main role of LH and FSH suppression in the drug's effect?

A: The action of Diphereline S.R. involves the continuous suppression of the pituitary hormones, Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH). This suppression leads to the removal of the stimulating signal to the gonads (testes and ovaries), which results in a reduction of circulating sex hormones, such as testosterone and estradiol.

---

Q: Does Diphereline S.R. cause hair loss or weight gain?

A: Regulatory documents indicate that increase in weight is a documented adverse event reported in clinical settings. Hair loss is not typically listed as a common or very common side effect in the official safety profile for the drug.

---

Q: Is Triptorelin used to treat infertility?

A: Triptorelin (the active ingredient) is officially indicated for use in managing certain aspects of female infertility as part of assisted reproductive technologies. It is typically used in combination with other medications, such as gonadotropins, during procedures like in-vitro fertilisation.

---

Q: Can this drug be taken with cold and flu medicine?

A: Official information regarding drug interactions focuses on medicines that may affect the heart's rhythm (those that prolong the QT interval) or medicines that raise prolactin levels. The product label does not specifically address non-prescription cold and flu medicines. It is important to discuss all concurrent medications with a healthcare professional.

---

Q: How long does the tumor flare reaction last?

A: For patients being treated for prostate cancer, a temporary worsening of symptoms called a tumor flare may occur. Official documentation notes that this reaction may be observed during the initial few weeks after starting treatment, before the full effect of hormone suppression is achieved.

Storage and Disposal Requirements

Diphereline S.R. must be stored strictly according to the conditions defined in the official regulatory labeling to maintain product stability.

Storage Component	Requirement
Temperature	Store below 25°C (77°F). Do not freeze.
Protection	Keep in the original container to protect from light.
Child Safety	Must be kept out of the sight and reach of children.
Post-Mixing Use	The suspension must be used immediately after reconstitution.

Disposal of unused or expired product must be handled in a controlled manner. All leftover medicine and related waste must be disposed of in accordance with local requirements and should not be thrown away via household waste or wastewater, as specified in official governmental documents.